Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
Publication|Articles|August 21, 2024
Pharmaceutical Technology Editorial Advisory Board
Listen
0:00 / 0:00
Key Takeaways
- The double-blind peer-review process ensures unbiased evaluation of technical articles by the Editorial Advisory Board (EAB).
- EAB members are experts from various pharmaceutical industry sectors, contributing to content quality and relevance.
Advertisement
Pharmaceutical Technology North America and Pharmaceutical Technology Europe magazines publish contributed technical articles that undergo a double-blind peer-review process involving members of our distinguished Editorial Advisory Boards (EAB). The EAB are specialists representing various facets of the pharmaceutical industry. EAB members review manuscripts, recommend subject matter and answer questions when they arise.
- Larry L. Augsburger, PhD, Professor Emeritus, University of Maryland School of Pharmacy
- Reinhard Baumfalk, Vice President Global Engineering Factory Automation, Emerson Automation Solutions
- Phil Borman, DSc, CChem, FRSC, Senior Director QbD & Digital Platform Portfolio & Technology Delivery, Medicine Development & Supply, Pharma R&D, GSK
- Evonne Brennan, Consultant at Evonne Brennan Consulting
- Rory Budihandojo, Independent GMP Consultant
- Christopher Burgess, Managing Director, Burgess Analytical Consultancy
- Metin Çelik, PhD, President, Pharmaceutical Technologies International (PTI)
- Robert Dream, Managing Director, HDR Company
- Manish Garg, PMP, PSM, Associate Director, IT Application, Serialization, Track & Trace, Hikma
- Sanjay Garg, PhD, Professor and Director, Centre for Pharmaceutical
Innovation and Development, University of South Australia - Filipe Gaspar, Vice-President Technology Intensification
Hovione - Ruey-ching (Richard) Hwang, PhD, Executive Director, Clinical Supply Operations, Pfizer Global R&D
- Henrik Johanning, CEO, Senior Consultant, Genau & More A/S
- Mansoor A. Khan, PhD, Regents Professor and Vice Dean, Presidential Impact Fellow, Rangel College of Pharmacy, Texas A&M University
- Heidi M. Mansour, PhD, Professor, Center for Translational Science, FIU Center for Translational Science
- R. Christian Moreton, PhD, Partner, FinnBrit Consulting
- Fernando J. Muzzio, PhD, Distinguished Professor, Chemical and Biochemical, Engineering Rutgers University
- Christa Myers, Senior Fellow–Aseptic & Sterile Products, CRB
- Moheb M. Nasr, PhD, Principal, Nasr Pharma Regulatory Consulting
- Siegfried Schmitt, PhD, Vice‑President Technical, PAREXEL International
Susan. J. Schniepp, Distinguished Fellow, Regulatory Compliance Associates. Click HERE for a spotlight on Sue Schniepp. - David R. Schoneker, President, Black Diamond Regulatory Consulting
- Aloka Srinivasan, Principal and Managing Partner, RAAHA LLC
- Griet Van Vaerenbergh, Marketing Manager Pharma Solid Dosage, GEA Process Engineering
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5